Elio
Pharmaceutical companies face regulatory and market pressure to report product carbon footprints (PCFs) for their chemical inputs, but existing life-cycle assessment (LCA) databases cover only a fraction of the specialty chemicals used in drug synthesis.
Public-source profile · Company ownership not verified. Sources & corrections
The short feature · 1 min read
Elio, at a glance
Built for · Pharmaceutical companies, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), and chemical suppliers needing…
Based on company material. Product claims are attributed to the company.
- 01
The problem
Leading LCA databases include carbon footprint data for only about 1,500 chemicals, primarily commodities. Pharmaceutical synthesis relies on thousands of specialized chemicals—coupling reagents, chiral ligands, catalysts, oxidants, and API building blocks—most of which lack PCF data.
Sources [1]
- 02
The product approach
Elio provides carbon footprint calculations for chemicals not covered by conventional LCA databases. The service models footprints from documented synthesis routes, following standards such as ISO 14067, TfS, and PAS 2090. Results are claimed to be auditable, deterministic, and scalable to tens of thousands of compounds.
Sources [1]
- 03
What stands out
Unlike conventional LCA methods, which rely on manual rebuilding or spend-based estimates, Elio automates PCF calculations using documented chemical routes from patents and literature. The company states its engine is fully recursive, resolving each input to an established dataset without AI-generated approximations or proxies.
Sources [1]
What could be hard to replicate?
A useful product is not automatically a moat. These mechanisms need evidence of a lasting advantage.
Data advantage
Company claimElio claims its PCF calculation engine is deterministic and grounded in documented synthesis routes, avoiding AI-generated or approximate data. This mechanism relies on curated chemical route data, which may create a data moat if competitors lack access to equivalent documentation or expertise.
Mechanism → evidence check
Does exclusive data improve the product in a way competitors cannot reproduce?
Sources [1]
The question to watch
What evidence shows that customers choose this product over alternatives, and keep using it?
Explore the evidence · 1 source
- [1] Elio company website
Company material · checked 5/10/2026
RuPhos Ligand No dataset tert-Butyl carbazate API building block No dataset L-Selectride Reducing agent No dataset Leading LCA databases cover about 1,500 chemicals, mostly commodities…
About
LCA data for the chemicals pharma actually uses: carbon footprints modelled from documented synthesis routes, for ecodesign and PCF reporting.
Profile sources, ownership & corrections
Company ownership is not verified
This profile was compiled from public sources and hasn't been verified by Elio. Claim it to correct the details, add your team and funding history, and request review of your company information.
Compiled from the company's own website.
Similar startups
Critical infrastructure such as power lines, pipelines, and railways requires regular inspection to prevent failures.
Simple Energy is an electric vehicle (EV) manufacturer focused on two-wheelers.
HrdWyr develops application-specific integrated circuits (AISoC) designed for edge computing.
Zipline operates a drone delivery service aimed at transporting food, groceries, and medicine quickly and without emissions.